Cargando…

Editorial: Risk factors in multiple myeloma identified before and during treatment: are we ready to personalize treatment?

Detalles Bibliográficos
Autores principales:	D’Agostino, Mattia, Terragna, Carolina, van Duin, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425881/ https://www.ncbi.nlm.nih.gov/pubmed/37588098 http://dx.doi.org/10.3389/fonc.2023.1247808

Ejemplares similares

Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?
por: Bolli, Niccolo, et al.
Publicado: (2020)

Risk Stratification Before and During Treatment in Newly Diagnosed Multiple Myeloma: From Clinical Trials to the Real-World Setting
por: Bonello, Francesca, et al.
Publicado: (2022)

Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
por: Oliva, Stefania, et al.
Publicado: (2020)

Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche
por: Solimando, Antonio Giovanni, et al.
Publicado: (2022)

Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives
por: Romano, Alessandra, et al.
Publicado: (2019)

Targeting the Endothelin-1 Receptors Curtails Tumor Growth and Angiogenesis in Multiple Myeloma
por: Russignan, Anna, et al.
Publicado: (2021)

Editorial: Molecular Mechanisms of Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Editorial: The role of the bone marrow microenvironment in multiple myeloma evolution and therapy
por: Schinke, Carolina, et al.
Publicado: (2023)

Editorial: T-cell directed therapies in multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2023)

Editorial: Exploiting the Immune System to Treat Multiple Myeloma: From Transplantation to Novel Treatment Approaches
por: van de Donk, Niels W. C. J., et al.
Publicado: (2020)

Treatment of Smoldering Multiple Myeloma: Ready for Prime Time?
por: Kim, E. Bridget, et al.
Publicado: (2020)

Editorial: Understanding the RNA Species in the Extracellular Vesicles of Multiple Myeloma
por: Chen, Maoshan, et al.
Publicado: (2022)

Editorial: Novel mechanisms for the treatment of AML before and after transplant
por: Kasner, Margaret T.
Publicado: (2022)

Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
por: Maiolino, Angelo, et al.
Publicado: (2023)

Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma?
por: Bertuglia, Giuseppe, et al.
Publicado: (2022)

Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma
por: Uckun, Fatih M.
Publicado: (2021)

Treatment Induced Cytotoxic T-Cell Modulation in Multiple Myeloma Patients
por: Barilà, Gregorio, et al.
Publicado: (2021)

Bispecific antibodies in multiple myeloma treatment: A journey in progress
por: Cho, Shih-Feng, et al.
Publicado: (2022)

How We Approach Smoldering Multiple Myeloma
por: Raje, Noopur, et al.
Publicado: (2020)

Impact of interval progression before autologous stem cell transplant in patients with multiple myeloma
por: Bao, Alicia, et al.
Publicado: (2023)

The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
por: Bonello, Francesca, et al.
Publicado: (2020)

Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True
por: D’Agostino, Mattia, et al.
Publicado: (2020)

Exosomes in the Pathogenesis and Treatment of Multiple Myeloma in the Context of the Bone Marrow Microenvironment
por: Chen, Tianzeng, et al.
Publicado: (2020)

The role of lymphoid tissue SPARC in the pathogenesis and response to treatment of multiple myeloma
por: Aly, Nesreen Amer Ramadan, et al.
Publicado: (2022)

Editorial: Molecular characteristics and personalized treatment for pediatric brain tumors
por: Feng, Weijun, et al.
Publicado: (2022)

Measuring teachers’ readiness to use ICT before the COVID-19 pandemic in Italy
por: D’Agostino, Antonella, et al.
Publicado: (2022)

Treatment of Multiple Myeloma in Elderly Patients: A Review of Literature and Practice Guidelines
por: Manapuram, Suresh, et al.
Publicado: (2018)

Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment
por: van der Schans, Jort J., et al.
Publicado: (2020)

Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment
por: Cerchione, Claudio, et al.
Publicado: (2022)

Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
por: Jayaweera, Shansa Pranami E., et al.
Publicado: (2021)

Adoptive NK Cell Therapy - a Beacon of Hope in Multiple Myeloma Treatment
por: Vu, Son Hai, et al.
Publicado: (2023)

Editorial: RNA recognition landscapes and anticancer drug targeting
por: Salvati, Erica, et al.
Publicado: (2023)

Editorial: Mutant p53 in Cancer Progression and Personalized Therapeutic Treatments
por: Timofeev, Oleg
Publicado: (2021)

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
por: Offidani, Massimo, et al.
Publicado: (2021)

Editorial: Exploring the Potential of PSMA-PET Imaging on Personalized Prostate Cancer Treatment
por: Ilhan, Harun, et al.
Publicado: (2022)

Development and Validation of an Algorithm to Identify Patients with Multiple Myeloma Using Administrative Claims Data
por: Princic, Nicole, et al.
Publicado: (2016)

Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma
por: Mancuso, Katia, et al.
Publicado: (2023)

Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma
por: Oliva, Stefania, et al.
Publicado: (2018)

Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies
por: D’Agostino, Mattia, et al.
Publicado: (2019)

Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor
por: Sgherza, Nicola, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s8ebs78atggpg15jn911l99dhs